Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.

ABSTRACT:

Purpose

The optimal treatment for medically inoperable stage I non-small-cell lung cancer (NSCLC) has not been defined.

Patients and methods

Cancer and Leukemia Group B trial 39904 prospectively assessed accelerated, once-daily, three-dimensional radiotherapy for early-stage NSCLC. The primary objectives were to define the maximally accelerated course of conformal radiotherapy and to describe the short-term and long-term toxicity of therapy. Entry was limited to patients with clinical stage T1N0 or T2N0 NSCLC (< 4 cm) and pulmonary dysfunction. The nominal total radiotherapy dose remained at 70 Gy, while the number of daily fractions in each successive cohort was reduced.

Results

Thirty-nine eligible patients were accrued (eight patients each on cohorts 1 to 4 and sev

SUBMITTER: Bogart JA 

PROVIDER: S-EPMC2815709 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature